Hepatitis is generally known as inflammation of liver which may result from infectious or non-infectious causes. Hepatitis A virus (HAV) is a single- stranded RNA virus in the picornivirus family. The fecal-oral route is the main transmission pathway for the Hepatitis A virus. This may occur through person- to- person or by eating contaminated food or drinking contaminated water. In very rare cases, it also has been transmitted through contaminated blood transfusions. Early symptoms of Hepatitis A can be headache, nausea, vomiting, abdominal pains, fever, rash, body aches and pains and dark colored urine. Following this jaundice (yellow colored skin and whites of the eyes), light stools and liver pain. Minimum age for vaccination is 1 year.
Anyone who has not been vaccinated or previously affected can also get infected with Hepatitis A virus. In high endemicity areas, most Hepatitis A infections occur during early childhood. Factors that proved as risk in intermediate and high endemicity areas include poor sanitation, lack of safe water, use of recreational drugs, living in a household with an infected person, being a sexual partner with someone with acute Hepatitis A infection and travelling to areas of high endemicity without being immunized.
Currently two types of vaccines are available internationally which includes Formaldehyde and Live attenuated vaccines. Formaldehyde are inactivated vaccines that are used in most countries. Monovalent inactivated vaccines are available in pediatric dose (0.5ml) or children aged 1 year to 15 years and in adult dose (1ml). Live attenuated vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
As per a report by WHO, most children experience asymptomatic infections while adults develop signs and symptoms of acute Hepatitis. When HAV infections is symptomatic, mostly it causes an acute self- limited hepatitis. However, relapses occur, and some patients may progress to liver failure that may be fatal. The estimated case of fatality ranges from 0.1% for children less than 15 years old to 0.3% among 15 to 39 years of age and 2.1% among adults 40 years of age or older.
According to the U.S. Department of Health and Human Services, Hepatitis A is a vaccine preventable, communicable disease of the liver caused by the Hepatitis A virus (HAV). Antibodies produced in response to Hepatitis A infection last through life and protect against recurrence of infection. Hepatitis A is best prevented through vaccination.
The Hepatitis A vaccine market is anticipated to record a CAGR of around 2.8% during the forecast period i.e. 2019-2027. The market is segmented by product type, industry and channel. By product type, the inactivated vaccine segment is anticipated to have leading share owing to its wide application and increasing prevalence of diseases. CLICK TO DOWNLOAD FREE SAMPLE
It has been notified that due to high prevalence of diseases, people have started to pay more attention to their overall health and the health for their children and get vaccinated on time in order to prevent risks of any kind sooner or later which is expected to boost the growth of the Hepatitis A vaccine market.
The number of government initiatives are increasing towards immunization. The government across different countries are providing facilities such as free vaccinations at a comparatively low cost. Government has also introduced various awareness schemes and plans to immunize people against Hepatitis A which is anticipated to boost the growth of the market.
The first dose of Hepatitis A vaccine gets effective immediately after 2 weeks of the vaccination and provides immunity, which is expected to boost the growth of the Hepatitis A vaccine market.
Vaccine development is a high cost process as it takes a lot of research and development, experimentation, certification, government permission etc. which is expected to hinder the growth of the market.
Development of a vaccine is not a cake walk, it includes going through extensive research, experimentation, continuous development and meeting the standards set by the government and following all the governmental rules and regulations etc. which is expected to impede the growth of the Hepatitis A vaccine market.
Our in- depth analysis of the Hepatitis A vaccine market includes the following segments:
On the basis of regional analysis, the Hepatitis A vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
Asia- Pacific region is expected to grow owing to rise in pediatric population and increase in awareness about vaccination. Various vaccination programs run by the government in developing countries is expected to propel the global hepatitis A vaccines market growth. North America is expected to grow significantly attributing to continuous efforts by market players and national organizations to promote hepatitis A vaccines.
The Hepatitis A vaccine market is further classified on the basis of region as follows:
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization